Parabilis Files for $100M IPO After Securing Up to $2.3B Regeneron Deal

Context Parabilis, formerly FogPharma, rebranded in 2024 to advance its Helicon™ platform, which designs stabilized helical peptides to block protein‑protein interactions or trigger targeted degradation. The platform couples AI‑driven modeling with high‑throughput peptide synthesis. The IPO filing, submitted to the SEC on Tuesday, lists a placeholder $100 million raise and seeks a Nasdaq listing under ticker PBLS. Regeneron’s agreement includes an upfront $75 million private placement at 90 % of the IPO price and milestone payments that could push the total value to $2.3 billion.

Key Facts - The Regeneron collaboration covers discovery and development of five antibody‑Helicon conjugate candidates targeting historically undruggable proteins. - Parabilis’ IPO prospectus shows a $100 million placeholder amount, to be amended before pricing. - In desmoid‑tumor studies, zolucatetide achieved tumor reduction in 100 % of patients; among those with at least two post‑baseline scans, the objective response rate was 74 %. - The desmoid data come from an open‑label Phase I/II dose‑expansion trial; no randomized control arm was reported, so the observed shrinkage is associative, not proven causal. - To date, more than 150 patients have received zolucatetide across solid‑tumor indications linked to Wnt/β‑catenin pathway alterations.

What It Means Investors should note that the IPO size will likely rise once underwriters set the final price, and the Regeneron deal provides non‑dilutive funding and validation of the Helicon technology. The desmoid tumor response suggests biological activity, but without a control group the 74 % ORR cannot be attributed solely to zolucatetide; further Phase III trials are needed to establish efficacy and safety. Proceeds will support continued dose expansion in familial adenomatous polyposis, hepatocellular carcinoma, and other rare tumors, as well as early‑stage work on ERG degraders and β‑catenin‑targeting programs.

Watch for the IPO pricing update, initiation of the planned Phase III desmoid trial, and any preclinical milestones disclosed under the Regeneron partnership.